Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Dacarbazine

Known as: Dakarbazin, Dacarbazinum, Dacarbazine - DTIC 
A drug that is used to treat Hodgkin lymphoma and malignant melanoma and is being studied in the treatment of other types of cancer. It attaches to… Expand
National Institutes of Health

Related topics

Related topics

40 relations

Broader (1)

Antineoplastic Agents, Alkylating

Narrower (11)

BELD protocolBiocarbazineDAV protocolDECAV protocol
Expand
Blood Coagulation DisordersCOPDAC RegimenCYVADIC protocolCyVADIC Regimen
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study.
PURPOSE Nivolumab, an anti-programmed death-1 monoclonal antibody, has demonstrated frequent and durable responses in relapsed… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Review
2018
Review
2018
Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD…
Purpose To investigate the progression-free survival (PFS) of patients with advanced Hodgkin lymphoma (HL) after a risk-adapted… Expand
Review
2017
Review
2017
P2X7 receptor antagonists: a patent review (2010–2015)
  • J. Park, Y. Kim
  • Expert opinion on therapeutic patents
  • 2017
    • Corpus ID: 23442805
ABSTRACT Introduction: The P2X7 receptor (P2X7R) is a unique subtype among the family of seven purinergic P2X receptors, which… Expand
Highly Cited
2015
Highly Cited
2015
Nivolumab in previously untreated melanoma without BRAF mutation.
BACKGROUND Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Highly Cited
2011
Highly Cited
2011
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
BACKGROUND Ipilimumab monotherapy (at a dose of 3 mg per kilogram of body weight), as compared with glycoprotein 100, improved… Expand
  • table 1
  • figure 2
  • table 2
  • table 3
Highly Cited
2006
Highly Cited
2006
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
PURPOSE Chemotherapy resistance in melanoma has been linked to antiapoptotic effects mediated by Bcl-2 protein. We evaluated… Expand
Highly Cited
2002
Highly Cited
2002
CO(2) capture by a task-specific ionic liquid.
Reaction of 1-butyl imidazole with 3-bromopropylamine hydrobromide, followed by workup and anion exchange, yields a new room… Expand
  • figure 1
  • figure 2
Highly Cited
2000
Highly Cited
2000
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.
PURPOSE To compare, in 305 patients with advanced metastatic melanoma, temozolomide and dacarbazine (DTIC) in terms of overall… Expand
Highly Cited
1999
Highly Cited
1999
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
PURPOSE Several single-institution phase II trials have reported that the Dartmouth regimen (dacarbazine, cisplatin, carmustine… Expand
Highly Cited
1994
Highly Cited
1994
A protein kinase involved in the regulation of inflammatory cytokine biosynthesis
Production of interleukin-1 and tumour necrosis factor from stimulated human monocytes is inhibited by a new series of pyridinyl… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE